Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients

The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device thrombosis in the Absorb BVS group. We investigat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beytullah Cakal, Sinem Cakal, Oguz Karaca, Mehmet Omaygenc, Filiz Yilmaz, Haci Gunes, Ozgur Ozcan, Arzu Yıldırım, Bilal Boztosun
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2020
Materias:	coronary artery disease percutaneous coronary intervention bioresorbable scaffolds Medicine R
Acceso en línea:	https://doaj.org/article/e3cd304ec9144aedbc315e1eb6589b5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e3cd304ec9144aedbc315e1eb6589b5f
record_format	dspace
spelling	oai:doaj.org-article:e3cd304ec9144aedbc315e1eb6589b5f2021-12-02T19:19:13ZLong-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients1734-93381897-429510.5114/aic.2020.101763https://doaj.org/article/e3cd304ec9144aedbc315e1eb6589b5f2020-12-01T00:00:00Zhttps://www.termedia.pl/Long-term-comparison-of-everolimus-vs-r-nnovolimus-eluting-bioresorbable-vascular-scaffolds-r-nin-real-world-patients,35,42699,1,1.htmlhttps://doaj.org/toc/1734-9338https://doaj.org/toc/1897-4295The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device thrombosis in the Absorb BVS group. We investigated whether all BVS platforms created equal outcomes. At 3-year follow-up novolimus-eluting BVS (Desolve Elixir Medical Corp., Sunnyvale, CA) achieved better outcomes compared with Absorb BVS. The scaffold thrombosis rate is still high with Absorb BVS despite pre- and post- dilatation. No scaffold thrombosis was present with Desolve BVS.Beytullah CakalSinem CakalOguz KaracaMehmet OmaygencFiliz YilmazHaci GunesOzgur OzcanArzu YıldırımBilal BoztosunTermedia Publishing Housearticlecoronary artery disease percutaneous coronary intervention bioresorbable scaffoldsMedicineRENAdvances in Interventional Cardiology, Vol 16, Iss 4, Pp 391-398 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	coronary artery disease percutaneous coronary intervention bioresorbable scaffolds Medicine R
spellingShingle	coronary artery disease percutaneous coronary intervention bioresorbable scaffolds Medicine R Beytullah Cakal Sinem Cakal Oguz Karaca Mehmet Omaygenc Filiz Yilmaz Haci Gunes Ozgur Ozcan Arzu Yıldırım Bilal Boztosun Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
description	The largest amount of evidence for bioresorbable vascular scaffold (BVS) use in clinical practice derives from Absorb trials and registries. Comparison of Absorb BVS with metallic stents resulted in increased rates of target lesion failure and device thrombosis in the Absorb BVS group. We investigated whether all BVS platforms created equal outcomes. At 3-year follow-up novolimus-eluting BVS (Desolve Elixir Medical Corp., Sunnyvale, CA) achieved better outcomes compared with Absorb BVS. The scaffold thrombosis rate is still high with Absorb BVS despite pre- and post- dilatation. No scaffold thrombosis was present with Desolve BVS.
format	article
author	Beytullah Cakal Sinem Cakal Oguz Karaca Mehmet Omaygenc Filiz Yilmaz Haci Gunes Ozgur Ozcan Arzu Yıldırım Bilal Boztosun
author_facet	Beytullah Cakal Sinem Cakal Oguz Karaca Mehmet Omaygenc Filiz Yilmaz Haci Gunes Ozgur Ozcan Arzu Yıldırım Bilal Boztosun
author_sort	Beytullah Cakal
title	Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
title_short	Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
title_full	Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
title_fullStr	Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
title_full_unstemmed	Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
title_sort	long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
publisher	Termedia Publishing House
publishDate	2020
url	https://doaj.org/article/e3cd304ec9144aedbc315e1eb6589b5f
work_keys_str_mv	AT beytullahcakal longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT sinemcakal longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT oguzkaraca longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT mehmetomaygenc longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT filizyilmaz longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT hacigunes longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT ozgurozcan longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT arzuyıldırım longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients AT bilalboztosun longtermcomparisonofeverolimusvsnovolimuselutingbioresorbablevascularscaffoldsinrealworldpatients
_version_	1718376885922037760

Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients

Ejemplares similares